论文部分内容阅读
慢性阻塞性肺疾病(COPD)是一种具有持续存在的气流受限为主要特征的疾病。急性加重增加了经济负担,更重要的是,加速了肺功能的减退,大大降低了生活质量,增加死亡率。至2020年,COPD将成为全球第三大疾病死亡原因。因此,COPD急性加重期(AECOPD)如何合理治疗,成为了当务之急。临床上广泛使用抗生素进行治疗,但是否使用抗生素,及何时应用抗生素,目前仍存在不少争议。本文结合国内外新近发表的文献,就有关AECOPD抗菌治疗的问题作一简述。15一、抗生素适用指征大约50%~70%的AECOPD患者存在病原学感染的证据[1]。根据最新GOLD指南[2],有以下情况的AECOPD患者建议应用
Chronic obstructive pulmonary disease (COPD) is a disease characterized by the persistence of airflow limitation. Acute exacerbations increase the financial burden and, more importantly, accelerate the decline of lung function, greatly reducing the quality of life and increasing the mortality rate. By 2020, COPD will be the third leading cause of death in the world. Therefore, acute exacerbations of COPD (AECOPD) how to treat properly, has become a top priority. The widespread use of antibiotics for clinical treatment, but whether to use antibiotics, and when antibiotics, there are still many controversies. In this paper, the recent literature published at home and abroad, on the AECOPD antibacterial therapy to make a brief description of the problem. 15 First, the antibiotic indications About 50% to 70% of AECOPD patients with evidence of etiological infection [1]. According to the latest GOLD guidelines [2], AECOPD patients with the following conditions are recommended